Argonautica Private Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Argonautica Private Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-463	Closed	-$330K	–	200
2024 Q4	$330K	Sell	463 -5	-1%	-$4.2K	0.11%	155
2024 Q3	$492K	Buy	468 +2	+0.4%	+$2.23K	0.16%	117
2024 Q2	$490K	Hold	466	–	–	0.17%	114
2024 Q1	$449K	Hold	466	–	–	0.16%	120
2023 Q4	$409K	Hold	466	–	–	0.17%	116
2023 Q3	$383K	Hold	466	–	–	0.17%	109
2023 Q2	$335K	Sell	466 -10	-2%	-$7.71K	0.15%	125
2023 Q1	$391K	Hold	476	–	–	0.2%	95
2022 Q4	$343K	Buy	+476	New	+$351K	0.18%	105

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Argonautica Private Wealth Management's REGN Position: Q1 2025 in Review

Argonautica Private Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 463 shares — an estimated $330K sold.

Argonautica Private Wealth Management first reported a position in REGN in Q4 2022 and held it in 9 quarters. The position peaked at $492K in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Argonautica Private Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Argonautica Private Wealth Management sold 463 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $330K.
Argonautica Private Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 9 quarters.
Argonautica Private Wealth Management's Regeneron Pharmaceuticals position peaked at $492K in Q3 2024.
1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Argonautica Private Wealth Management's 13F filing for Q1 2025, filed 6 May 2025.